You can buy or sell ChemoCentryx and other stocks, options, ETFs, and crypto commission-free!
ChemoCentryx, Inc. Common Stock, also called ChemoCentryx, is a biopharmaceutical company engages in the development and commercialization of medicines. Read More It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.
Mountain View, California
52 Week High
52 Week Low
Seeking AlphaMay 23
ChemoCentryx And Aurinia In Focal Segmental Glomerulosclerosis: Strength In Numbers
Due to the complexity and heterogeneity of FSGS, it is likely that more than one therapeutic agents including CCX140 may be needed to provide clinically effective benefits to FSGS patients.
Yahoo FinanceMay 9
Hedge Funds Have Never Been More Bullish On ChemoCentryx Inc (CCXI)
The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow.
The Motley FoolMay 7
ChemoCentryx Inc (CCXI) Q1 2019 Earnings Call Transcript
ChemoCentryx Inc (NASDAQ:CCXI) Q1 2019 Earnings Call , 5:00 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good afternoon and welcome to the ChemoCentryx First Quarter 2019 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. As a reminder, this conference will be recorded. I would now like to turn the call over to Bill Slattery of Burns McClellan. Mr...
Expected Aug 8, After Hours